Ascendis Pharma A/S - ASND Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Moderate Buy
Consensus Price Target: $173.25
Forecasted Upside: 27.48%
Number of Analysts: 8
Breakdown:
0 Sell Ratings
1 Hold Ratings
7 Buy Ratings
0 Strong Buy Ratings

^$135.90 As of 04/26/2024 09:52 PM ET

▼ -1.03 (-0.75%)

1 month | 3 months | 12 months

Get New Ascendis Pharma A/S Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ASND and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ASND

^$173.25

▲ +27.48% Upside Potential

This price target is based on 8 analysts offering 12 month price targets for Ascendis Pharma A/S in the last 3 months. The average price target is $173.25, with a high forecast of $260.00 and a low forecast of $113.00. The average price target represents a 27.48% upside from the last price of $135.90.

Current Consensus is Moderate Buy

The current consensus among 8 contributing investment analysts is to moderate buy stock in Ascendis Pharma A/S. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
7 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

11/6/2022

0 strong buy ratings
7 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

2/4/2023

0 strong buy ratings
7 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

5/5/2023

0 strong buy ratings
7 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

8/3/2023

0 strong buy ratings
7 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

11/1/2023

0 strong buy ratings
7 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

1/30/2024

0 strong buy ratings
7 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

3/30/2024

0 strong buy ratings
7 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

4/29/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/22/2024	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$116.00 ➝ $116.00	Low
4/18/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$173.00	Low
4/2/2024	JPMorgan Chase & Co.	Boost Target	Overweight ➝ Overweight	$165.00 ➝ $167.00	Low
4/1/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$173.00	Low
3/15/2024	Wells Fargo & Company	Boost Target	Overweight ➝ Overweight	$196.00 ➝ $260.00	N/A
2/8/2024	Citigroup	Boost Target	Buy ➝ Buy	$146.00 ➝ $182.00	Low
2/8/2024	Wedbush	Boost Target	Outperform ➝ Outperform	$207.00 ➝ $225.00	Low
2/6/2024	Cantor Fitzgerald	Boost Target	Overweight ➝ Overweight	$152.00 ➝ $173.00	Low
1/8/2024	Wedbush	Reiterated Rating	Outperform	$202.00 ➝ $207.00	Low
12/20/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$152.00	Low
12/20/2023	Wedbush	Boost Target	Outperform ➝ Outperform	$200.00 ➝ $202.00	Low
12/20/2023	Jefferies Financial Group	Initiated Coverage	Buy	$150.00	Low
12/19/2023	Wells Fargo & Company	Boost Target	Overweight ➝ Overweight	$137.00 ➝ $149.00	Low
11/9/2023	Morgan Stanley	Boost Target	Equal Weight ➝ Equal Weight	$113.00 ➝ $116.00	Low
11/8/2023	Wedbush	Reiterated Rating	Outperform ➝ Outperform	$192.00	Low
10/31/2023	Wedbush	Reiterated Rating	Outperform	$192.00	Low
10/9/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy		Low
9/15/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$152.00	Low
9/14/2023	Wedbush	Reiterated Rating	Outperform	$192.00	Low
9/7/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$152.00	Low
9/7/2023	Bank of America	Boost Target		$107.00 ➝ $113.00	Low
9/6/2023	Morgan Stanley	Boost Target	Equal Weight ➝ Equal Weight	$109.00 ➝ $113.00	Low
9/6/2023	Wedbush	Boost Target	Outperform ➝ Outperform	$187.00 ➝ $192.00	Low
9/6/2023	Wells Fargo & Company	Lower Target	Overweight ➝ Overweight	$139.00 ➝ $134.00	Low
8/7/2023	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$109.00	Low
7/31/2023	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$109.00	Low
7/24/2023	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$109.00	Low
6/2/2023	Wedbush	Boost Target		$186.00 ➝ $187.00	Low
4/28/2023	3M	Reiterated Rating	Maintains		Low
4/28/2023	Cantor Fitzgerald	Boost Target		$142.00 ➝ $152.00	Low
4/12/2023	Morgan Stanley	Lower Target		$108.00 ➝ $107.00	Low
4/5/2023	Citigroup	Lower Target	Buy	$163.00 ➝ $146.00	Low
4/5/2023	Oppenheimer	Downgrade	Outperform ➝ Market Perform		Low
4/4/2023	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$151.00 ➝ $108.00	Low
4/3/2023	Bank of America	Lower Target	Buy	$132.00 ➝ $92.00	Low
4/3/2023	Credit Suisse Group	Downgrade	Outperform ➝ Neutral		Low
2/17/2023	Credit Suisse Group	Reiterated Rating	Outperform	$130.00	Low
2/17/2023	Morgan Stanley	Boost Target	Overweight	$148.00 ➝ $151.00	Low
1/3/2023	Wells Fargo & Company	Boost Target	Overweight	$169.00 ➝ $177.00	Low
11/15/2022	Morgan Stanley	Boost Target	Overweight	$146.00 ➝ $148.00	Low
11/14/2022	SVB Leerink	Lower Target	Outperform	$168.00 ➝ $148.00	Low
11/14/2022	Wedbush	Boost Target	Outperform	$151.00 ➝ $164.00	Low
11/7/2022	Wells Fargo & Company	Lower Target	Overweight	$172.00 ➝ $169.00	Low
11/3/2022	Morgan Stanley	Lower Target	Overweight	$148.00 ➝ $146.00	Low
11/3/2022	Oppenheimer	Boost Target		$144.00 ➝ $150.00	Low
11/3/2022	Wedbush	Boost Target		$144.00 ➝ $151.00	Low
11/3/2022	Credit Suisse Group	Boost Target	Outperform	$123.00 ➝ $130.00	Low
11/3/2022	Citigroup	Boost Target	Buy	$157.00 ➝ $163.00	Low
10/27/2022	Cantor Fitzgerald	Lower Target		$184.00 ➝ $182.00	Low
10/20/2022	The Goldman Sachs Group	Initiated Coverage	Buy	$174.00	Low
9/22/2022	Wells Fargo & Company	Boost Target	Overweight	$167.00 ➝ $172.00	Low
9/21/2022	Cantor Fitzgerald	Reiterated Rating	Overweight		Low
8/30/2022	Berenberg Bank	Reiterated Rating	Buy	$166.00	Low
8/11/2022	Morgan Stanley	Lower Target	Overweight	$152.00 ➝ $148.00	Low
8/11/2022	Oppenheimer	Lower Target	Outperform	$154.00 ➝ $144.00	Low
8/11/2022	SVB Leerink	Lower Target	Outperform	$174.00 ➝ $168.00	Low
5/12/2022	Cantor Fitzgerald	Lower Target		$230.00 ➝ $180.00	High
5/12/2022	Oppenheimer	Lower Target		$166.00 ➝ $154.00	High
5/12/2022	Wells Fargo & Company	Lower Target		$190.00 ➝ $176.00	High
5/12/2022	Credit Suisse Group	Lower Target		$194.00 ➝ $123.00	High
5/12/2022	Citigroup	Lower Target		$187.00 ➝ $158.00	High
4/1/2022	Cantor Fitzgerald	Reiterated Rating	Overweight		N/A
3/28/2022	Wedbush	Reiterated Rating	Outperform		Low
3/15/2022	Morgan Stanley	Boost Target	Overweight	$180.00 ➝ $197.00	High
3/15/2022	SVB Leerink	Boost Target	Outperform	$190.00 ➝ $193.00	High
3/15/2022	Bank of America	Upgrade	Neutral ➝ Buy	$148.00 ➝ $161.00	High
3/14/2022	Wells Fargo & Company	Boost Target		$170.00 ➝ $190.00	High
3/14/2022	Credit Suisse Group	Boost Target	Outperform	$188.00 ➝ $194.00	High
3/7/2022	Morgan Stanley	Lower Target	Overweight	$197.00 ➝ $180.00	Low
3/3/2022	Wedbush	Lower Target	Outperform	$128.00 ➝ $117.00	High
3/3/2022	Wells Fargo & Company	Lower Target	Overweight	$176.00 ➝ $170.00	High
3/3/2022	Credit Suisse Group	Lower Target	Outperform	$196.00 ➝ $188.00	High
2/28/2022	Citigroup	Initiated Coverage	Buy	$187.00	High
2/14/2022	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$170.00	Medium
1/13/2022	Wedbush	Lower Target		$191.00 ➝ $186.00	High
1/6/2022	Cowen	Initiated Coverage	Market Perform		Medium
12/16/2021	Wedbush	Reiterated Rating	Outperform	$191.00	High
12/8/2021	Wells Fargo & Company	Initiated Coverage	Overweight	$176.00	Medium
11/18/2021	Cantor Fitzgerald	Reiterated Rating	Overweight		Low
11/15/2021	SVB Leerink	Boost Target	Outperform	$182.00 ➝ $190.00	Medium
11/11/2021	Credit Suisse Group	Lower Target	Outperform	$185.00 ➝ $179.00	Low
10/20/2021	Bank of America	Downgrade	Buy ➝ Neutral	$164.00 ➝ $169.00	High
8/26/2021	Wedbush	Reiterated Rating	Buy	$187.00	High
8/26/2021	Morgan Stanley	Boost Target	Overweight	$197.00 ➝ $204.00	High
8/26/2021	JPMorgan Chase & Co.	Boost Target	Overweight	$172.00 ➝ $175.00	High
8/26/2021	Credit Suisse Group	Boost Target	Outperform	$178.00 ➝ $185.00	High
8/26/2021	SVB Leerink	Boost Target	Outperform	$178.00 ➝ $182.00	High
7/21/2021	SVB Leerink	Lower Target	Outperform	$181.00 ➝ $178.00	Low
7/8/2021	Oppenheimer	Reiterated Rating	Hold		Medium
6/14/2021	SVB Leerink	Lower Target	Positive ➝ Outperform	$191.00 ➝ $181.00	High
6/14/2021	Wedbush	Lower Target	Outperform	$219.00 ➝ $189.00	High
6/14/2021	Morgan Stanley	Lower Target	Overweight	$201.00 ➝ $197.00	High
5/28/2021	Credit Suisse Group	Boost Target	Outperform	$176.00 ➝ $178.00	High
5/28/2021	Morgan Stanley	Boost Target	Overweight	$199.00 ➝ $201.00	Medium
3/30/2021	Oppenheimer	Downgrade	Outperform ➝ Market Perform		Low
3/11/2021	Credit Suisse Group	Lower Target	Outperform	$178.00 ➝ $176.00	Low
3/11/2021	Stifel Nicolaus	Initiated Coverage	Buy		High
12/17/2020	Berenberg Bank	Initiated Coverage	Buy	$216.00	Low
11/13/2020	Morgan Stanley	Boost Target	Overweight	$194.00 ➝ $199.00	Low
11/12/2020	Wells Fargo & Company	Boost Target	Overweight	$176.00 ➝ $190.00	High
11/12/2020	Credit Suisse Group	Boost Target	Outperform	$158.00 ➝ $178.00	High
11/12/2020	SVB Leerink	Boost Target	Outperform	$173.00 ➝ $191.00	High
10/13/2020	Morgan Stanley	Boost Target	Overweight	$179.00 ➝ $194.00	Low
9/30/2020	Wedbush	Boost Target	Outperform	$187.00 ➝ $206.00	Medium
9/14/2020	JPMorgan Chase & Co.	Initiated Coverage	Overweight		Medium
8/31/2020	Morgan Stanley	Boost Target	Overweight	$177.00 ➝ $179.00	High
8/28/2020	Credit Suisse Group	Boost Target	Outperform	$154.00 ➝ $158.00	Medium
7/15/2020	Morgan Stanley	Lower Target	Overweight	$181.00 ➝ $177.00	Low
6/26/2020	Wedbush	Initiated Coverage	Buy	$188.00	Low
5/21/2020	Morgan Stanley	Boost Target	Overweight	$180.00 ➝ $181.00	Low
5/20/2020	CSFB	Boost Target	Outperform	$149.00 ➝ $154.00	Medium
5/20/2020	SVB Leerink	Boost Target	Outperform	$170.00 ➝ $173.00	Low
5/20/2020	Credit Suisse Group	Boost Target	Outperform	$149.00 ➝ $154.00	High
5/20/2020	Oppenheimer	Lower Target	Outperform	$219.00 ➝ $208.00	High
4/20/2020	SVB Leerink	Boost Target	Positive ➝ Outperform	$152.00 ➝ $170.00	High
4/20/2020	JPMorgan Chase & Co.	Boost Target	Overweight	$145.00 ➝ $150.00	High
4/20/2020	Oppenheimer	Boost Target	Outperform	$199.00 ➝ $219.00	High
4/20/2020	Credit Suisse Group	Boost Target	In-Line ➝ Outperform	$139.00 ➝ $149.00	High
4/20/2020	Cantor Fitzgerald	Boost Target	Overweight	$185.00 ➝ $201.00	High
4/20/2020	Stifel Nicolaus	Boost Target	Buy	$146.00 ➝ $171.00	High
4/2/2020	Morgan Stanley	Lower Target	Overweight	$181.00 ➝ $180.00	Medium
3/27/2020	Bank of America	Reiterated Rating	Buy	$145.00	Medium
3/19/2020	Oppenheimer	Initiated Coverage	Outperform	$199.00	Low
2/26/2020	Morgan Stanley	Boost Target	Overweight	$148.00 ➝ $181.00	Low
1/17/2020	Morgan Stanley	Boost Target	Overweight	$140.00 ➝ $148.00	Medium
12/17/2019	Morgan Stanley	Boost Target	Overweight	$134.00 ➝ $140.00	High
12/3/2019	SVB Leerink	Reiterated Rating	Positive ➝ Outperform	$140.00 ➝ $152.00	Medium
11/19/2019	Wedbush	Reiterated Rating	Buy	$186.00	High
10/22/2019	Wedbush	Lower Target	Positive ➝ Outperform	$191.00 ➝ $186.00	High
10/11/2019	Morgan Stanley	Initiated Coverage	Overweight	$128.00	High
9/24/2019	Wedbush	Set Target	Buy	$191.00	Low
8/29/2019	JPMorgan Chase & Co.	Boost Target	Overweight	$143.00 ➝ $152.00	High
6/28/2019	Wedbush	Reiterated Rating	Buy	$223.00	Low
6/10/2019	Wedbush	Set Target	Buy	$223.00	Low
6/3/2019	Wedbush	Boost Target	Outperform	$219.00 ➝ $223.00	High
5/20/2019	Wedbush	Set Target	Buy	$219.00	Medium

(Data available from 4/29/2019 forward)

News Sentiment Rating

0.72 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

15 very positive mentions
10 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

10/2/2023

2 very positive mentions
4 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

11/1/2023

4 very positive mentions
7 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

12/1/2023

13 very positive mentions
7 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

12/31/2023

14 very positive mentions
4 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

1/30/2024

15 very positive mentions
19 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

2/29/2024

7 very positive mentions
4 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

3/30/2024

9 very positive mentions
12 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

4/29/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Today's Range

Now: $135.90

$133.39

$139.80

50 Day Range

MA: $148.47

$135.90

$159.40

52 Week Range

Now: $135.90

$66.03

$161.00

Volume

226,100 shs

Average Volume

366,686 shs

Market Capitalization

$7.91 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.5

Frequently Asked Questions

What sell-side analysts currently cover shares of Ascendis Pharma A/S?: The following Wall Street sell-side analysts have issued stock ratings on Ascendis Pharma A/S in the last year: Bank of America Co., Cantor Fitzgerald, Citigroup Inc., HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, StockNews.com, Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for ASND.
What is the current price target for Ascendis Pharma A/S?: 8 Wall Street analysts have set twelve-month price targets for Ascendis Pharma A/S in the last year. Their average twelve-month price target is $173.25, suggesting a possible upside of 27.5%. Wells Fargo & Company has the highest price target set, predicting ASND will reach $260.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $113.00 for Ascendis Pharma A/S in the next year.
View the latest price targets for ASND.
What is the current consensus analyst rating for Ascendis Pharma A/S?: Ascendis Pharma A/S currently has 1 hold rating and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ASND.
What other companies compete with Ascendis Pharma A/S?: Other companies that are similar to Ascendis Pharma A/S include Legend Biotech, Roivant Sciences, Cerevel Therapeutics, Intra-Cellular Therapies and Viking Therapeutics. Learn More about companies similar to Ascendis Pharma A/S.
How do I contact Ascendis Pharma A/S's investor relations team?: Ascendis Pharma A/S's physical mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The biotechnology company's listed phone number is (457) 022-2244 and its investor relations email address is [email protected]. The official website for Ascendis Pharma A/S is www.ascendispharma.com. Learn More about contacing Ascendis Pharma A/S investor relations.

Ascendis Pharma A/S - ASND Stock Price Target and Predictions

Analyst Price Target for ASND

Current Consensus is Moderate Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.72 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Ascendis Pharma A/S?

What is the current price target for Ascendis Pharma A/S?

What is the current consensus analyst rating for Ascendis Pharma A/S?

What other companies compete with Ascendis Pharma A/S?

How do I contact Ascendis Pharma A/S's investor relations team?